Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication April 12, 2021
- Revision received October 6, 2021
- Published online June 30, 2022.
Article Versions
- previous version (November 5, 2021 - 09:42).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2022 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
Author Information
- Christine E. Mona1,2,3,
- Matthias R. Benz1,2,
- Firas Hikmat1,
- Tristan R. Grogan4,
- Katharina Lueckerath1,2,3,
- Aria Razmaria1,
- Rana Riahi5,
- Roger Slavik1,
- Mark D. Girgis6,
- Giuseppe Carlucci1,2,
- Kimberly A. Kelly7,
- Samuel W. French2,5,
- Johannes Czernin1,2,3,
- David W. Dawson*,2,5 and
- Jeremie Calais*,1,2,3
- 1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
- 2Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California;
- 3Institute of Urologic Oncology, UCLA, Los Angeles, California;
- 4Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California;
- 5Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California;
- 6Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, California; and
- 7Department of Biomedical Engineering, University of Virginia School of Engineering and Applied Sciences, and Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia
- For correspondence or reprints, contact Jeremie Calais (jcalais{at}mednet.ucla.edu) or Christine E. Mona (cmona{at}mednet.ucla.edu).
↵* Contributed equally to this work.
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic Patients
- Expression of fibroblast activation protein-{alpha} in human deep venous thrombus
- Imaging of Tumor Stroma Using 68Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial
- Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma
- Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-{alpha} (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
- Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake